{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Supine PR Interval - Value ≥300 msec"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Supine PR Interval - %Chg ≥25/50%"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Supine QRS Interval - Value ≥140 msec"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Supine QRS Interval - %Chg ≥50%"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Supine QT Interval - Value ≥500 msec"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Supine QTcF - 470<Value≤480 msec"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Supine QTcF - 480<Value≤500 msec"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Supine QTcF - Value>500 msec"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Supine QTcF - 30<Chg≤60 msec"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Supine QTcF - Chg>60 msec"}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"description":"ECG data (PR interval, QRS interval, QT interval, and QTcF) were obtained with participant in the supine position. The pre-specified categorical analysis criteria in ECG, were PR interval: value ≥300 milliseconds (msec), percentage change ≥25/50%; QRS interval: value ≥140 msec, percentage change ≥50%; QT interval: value ≥500 msec; QTcF interval: 470\\< value ≤480 msec, 480\\< value ≤500 msec, value \\>500 msec, and 30\\< change ≤60 msec, change \\>60 msec.","groups":[{"description":"During the 12-week treatment period, participants receive a total of 5 SC doses of PF-06946860 Q3W.","id":"OG000","title":"PF-06946860 Q3W"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Overall number of participants analyzed included participants evaluated against pre-defined criteria for ECGs.","reportingStatus":"POSTED","timeFrame":"From Day 1 up to Week 24","title":"Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities","type":"PRIMARY","unitOfMeasure":"Participants"}